Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index

Ana I. Casanegra, Julie A. Stoner, Alfonso J. Tafur, H. Anne Pereira, Suman W. Rathbun, Andrew W. Gardner

Research output: Contribution to journalArticle

4 Scopus citations


The aim of this study was to determine if galectin-3 levels were different between participants with peripheral artery disease (PAD) and controls, and to describe its relationship with markers of early atherosclerosis. Sixty participants were recruited into two groups: a PAD group (n=31), ankle-brachial index (ABI) ≤0.90 and a normal ABI group (n=29), ABI 1.0-1.4. PAD participants were older (68.6 vs 61.8 years, p=0.037), more commonly men (68% vs 38%, p=0.02), and with more cardiovascular risk factors (p<0.001). Galectin-3 was 22% higher in PAD participants (mean±SD: 17.6±4.7 vs 14.4±4.1 ng/mL, p<0.01). The odds ratio for galectin-3 in PAD to be 1 ng/mL higher than the participants with normal ABI was 1.19, after adjusting by age and gender (p=0.014). High-sensitivity C-reactive protein (hs-CRP) and homeostatic model assessment (HOMA) were positively associated with galectin-3 in the age- and gender-adjusted model, while arterial elasticity and microalbuminuria were not. In conclusion, galectin-3 levels were higher in participants with PAD.

Original languageEnglish (US)
Pages (from-to)437-444
Number of pages8
JournalVascular Medicine (United Kingdom)
Issue number5
StatePublished - Oct 1 2016


All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this